September 6, 2024 – Page 4

Accredited Solutions Executes Indication of Interest ( IOI ) to Acquire a Leading Fintech Company Focused on B2B Distribution of e-Gift Cards

Written by Customer Service on September 6, 2024. Posted in Public Companies.

NEW YORK, NY, Sept. 06, 2024 (GLOBE NEWSWIRE) — Accredited Solutions, Inc. (OTC: ASII) (“Accredited Solutions” or the “Company”), the parent company of Diamond Creek Water, is excited to announce the execution of an Indication of Interest (“IOI”) letter for the acquisition of a leading US-based B2B distributor of third party e-gift cards. This target company (“Target”) generated $33.7 million in sales in 2023 and is on track for a 2024 revenue run-rate of $42.5 million and is profitable on a net income basis. The potential acquisition aligns with Accredited Solutions’ growth strategy, which includes synergistic opportunities to accelerate target’s growth through the injection of additional capital and resources. By integrating the marketing and administrative functions of both companies...

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Written by Customer Service on September 6, 2024. Posted in Public Companies.

WASHINGTON, Sept. 06, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced private placement, priced at-the-market under Nasdaq rules, of an aggregate of 2,898,551 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 2,898,551 shares of common stock and short-term series B warrants to purchase up to 2,898,551 shares of common stock at a purchase price of $1.38 per share (or per common stock equivalent in lieu thereof) and accompanying warrants. The series A warrants and short-term series B warrants have an exercise price of $1.38 per share and will be exercisable beginning on the effective...

dLocal appoints Carlos Menendez as Chief Operating Officer

Written by Customer Service on September 6, 2024. Posted in Public Companies.

dLocal strengthens leadership team with the appointment of Carlos Menendez as new COO and ongoing service of Jacobo Singer as Board Member following a transition period MONTEVIDEO, Uruguay, Sept. 06, 2024 (GLOBE NEWSWIRE) — dLocal, a leading cross-border payment platform specializing in high-growth markets, announces the appointment of Carlos Menendez as Chief Operating Officer (COO), effective immediately. Jacobo Singer, who currently serves as COO and Co-President, will continue to serve in both roles during a transition period until December 15, 2024, at which time he will step down from both roles. During this transition period, Carlos and Jacobo will work closely to ensure a smooth handover of responsibilities. Following the transition period, Jacobo will continue to serve as a member of our Board of Directors. “We are excited...

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

Written by Customer Service on September 6, 2024. Posted in Public Companies.

Results from this trial are expected in 2025 SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease. “We are excited to initiate this trial of VTX3232 in patients with early Parkinson’s disease,” said Mark Forman, MD, PhD, Chief Medical Officer. “There is a compelling body of evidence from the literature suggesting a strong mechanistic rationale for targeting NLRP3-driven neuroinflammation in Parkinson’s disease and that microglial NLRP3 activation may play an important role in Parkinson’s...

Lixiang Education Announces Change of Chief Financial Officer

Written by Customer Service on September 6, 2024. Posted in Public Companies.

LISHUI, China, Sept. 06, 2024 (GLOBE NEWSWIRE) — Lixiang Education Holding Co., Ltd. (NASDAQ: LXEH) (the “Company”), a prestigious private education service provider in China, today announced that Mr. Luoyuan Ye resigned as the Chief Financial Officer (“CFO”) of the Company with effect from August 31, 2024 and will remain as the consultant to the Company. Mr. Zhifu Yang was appointed as the CFO with effect from September 2, 2024. Mr. Zhifu Yang, aged 42, has over 15 years of work experience in financial accounting and financial management. Since October 2021, Mr. Yang has been acting as the chief financial officer in Beijing Pengxiang Tianxia Education Technology Co., Ltd. From October 2019 to October 2021, Mr. Yang worked in Zhi Jin Education Consulting Co., Ltd as the chief financial officer. Before entering into the vocational...

Froneri Israel Orders SaverOne Systems to Provide Safety Coverage for its Entire Fleet

Written by Customer Service on September 6, 2024. Posted in Public Companies.

Petah Tikvah, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) — SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company that develops and sells advanced transportation safety solutions, today announced that Froneri extended its agreement with SaverOne and will update and equip SaverOne systems across its entire fleet of employee vehicles and distribution trucks in Israel. Froneri was among the first companies to install the SaverOne System within its fleet to counteract driver distraction, back in 2021. Froneri is a UK-headquartered and leading manufacturer of ice cream with global sales. The company is jointly owned by Nestle Worldwide and R&R Ice Cream. Mr. Ori Gilboa, CEO of SaverOne, commented, “We are delighted that Froneri, an early customer of ours, is expanding its use of the SaverOne System across its entire...

PTX Metals Inc. Announces Effective Date of Share Consolidation

Written by Customer Service on September 6, 2024. Posted in Public Companies.

TORONTO, Sept. 06, 2024 (GLOBE NEWSWIRE) — PTX Metals Inc. (CSE: PTX) (OTCQB: PANXF, Frankfurt: 9PF) (“PTX Metals” or the “Company”) announces that it will consolidate its common shares (the “Common Shares”) on the basis of four (4) pre consolidated Common Shares into one (1) post consolidated Common Share (the “Share Consolidation”), effective as of the open of business on September 11, 2024 (the “Effective Date“). As of the Effective Date, the Company will commence trading on the Canadian Securities Exchange (the “Exchange”) on a consolidated basis and the new CUSIP and ISIN number will be 69380V205 and CA69380V2057, respectively. The Share Consolidation will result in the number of issued and outstanding Common Shares being reduced from the current outstanding 370,213,062 Common Shares to approximately 92,553,265...

Hurco Reports Third Quarter Results for Fiscal Year 2024

Written by Customer Service on September 6, 2024. Posted in Earnings Releases And Operating Results.

INDIANAPOLIS, Sept. 06, 2024 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the third fiscal quarter ended July 31, 2024. Hurco recorded a net loss of $9,596,000, or $(1.47) per diluted share, in the third quarter of fiscal year 2024, which included a non-cash tax valuation allowance of $8,158,000 recorded in provision for income taxes. This net loss of $9,596,000 for the third quarter of fiscal 2024 compares to net income of $260,000, or $0.04 per diluted share, for the corresponding period in fiscal year 2023. For the nine months of fiscal year 2024, Hurco reported a net loss of $15,166,000, or $(2.33) per diluted share, compared to net income of $1,967,000, or $0.30 per diluted share, for the corresponding period in fiscal year 2023. The net loss for the nine months of fiscal 2024 also included...

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Written by Customer Service on September 6, 2024. Posted in Public Companies.

New clinical efficacy and safety data for arimoclomol as a possible treatment for Niemann-Pick disease type C, including from long-term and real-world settings, demonstrate clinically meaningful reduction in disease progression Arimoclomol was well tolerated during the Open Label Extension trial and Early Access Program with no safety signals identified PK modeling studies showed that administration of OLPRUVA while fasting vs fed results in higher drug exposure which may allow for lower effective dosages when taken without food CELEBRATION, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced the presentation of five posters at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium. Four posters...

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

Written by Customer Service on September 6, 2024. Posted in Public Companies.

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming investor and scientific conferences. Event: H.C. Wainwright 26th Annual Global Investment Conference (New York, NY) Presentation: September 9, 2024 at 2:00 p.m. ET Format: Company presentation and one-on-one meetings Event: 6th Annual Exosome-Based Therapeutic Summit (Boston, MA) Presentation: September 17-19, 2024 Format: Company presentation and industry panel Event: 2024 Cantor Fitzgerald’s Global Healthcare Conference (New York, NY) Presentation: September 18, 2024 at 8:35 a.m. ET Format: Fireside chat and one-on-one meetings Capricor...

Day: September 6, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice